The Finance and Tax Advisory Committee (FTAC) guides the BIA’s policies and initiatives to create a supportive financial environment for UK bioscience companies. The committee is the forum where BIA members can directly input into policy development and interactions with Government on finance and tax matters.

Priorities for 2021:

Connect: We will continue to invite guest speakers and recruit new members from the BIA membership, particularly specialists in areas we don’t currently cover (e.g. accounting and grants), members outside the golden triangle, and companies working in emerging sub-sectors of our industry, such as digital health. 
 
Inform/Support: We will pro-actively engage with HM Treasury/HMRC on anticipated tax changes, particularly capital gains tax and the implementation of the PAYE cap, to ensure the BIA is first in the conversation. We will follow the National Security and Investment Bill and inform the BIA’s representations to Government. We will work with the British Business Bank and Office for Life Sciences, and other partners and stakeholders, to identify actions that could increase the availability of finance for our sector.
 
Expert advice: We will look at issues related to grant funding and how BIA members can be supported to access it. We will keep members informed about the above issues and how they might need to respond.

 

Committee Chair: Colin Hailey, Partner, Confluence Tax

Committee Vice-Chair: Melissa Strange, Chief Financial Officer, Closed Loop Medicine

For more information contact Dr Martin Turner, Head of Policy and Public Affairs

Member list

BioCity Group Limited

BioCity Group specialises in the creation and development of life science businesses. It provides homes and access to high-end equipment, shared services, training, business support and access to investment for new and growing bioscience businesses.

Confluence Tax LLP

Confluence Tax LLP specialises in high quality and cost effective tax advice tax advice for early stage technology and life science companies.

F-star

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer.

FTI Consulting

FTI is designed to address the interrelated challenges that can affect an organization’s enterprise value

GE Healthcare UK Ltd

GE is a global infrastructure, finance and media company taking on the world's toughest challenges.

Ingenza Ltd

Ingenza Ltd. is an industrial biotechnology company based in Roslin, Edinburgh, UK. The company has a broad customer base within the chemicals, pharmaceuticals, food, feed and fuel industries where it applies its proprietary synthetic biology to manufacture industrial products.

Karus Therapeutics Ltd

Karus is an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer.

Osborne Clarke

We are proud of our heritage, but we're firmly focused on becoming the law firm of the future for our clients, and our people.

Oxford BioMedica plc

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.

Pinsent Masons LLP

Pinsent Masons is a full-services law firm with offices across the UK, Europe and Asia offering the very highest level of market intelligence and experience.

ReNeuron Group Plc

ReNeuron are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Silicon Valley Bank

Silicon Valley Bank provides unique and flexible financial solutions to some of the most innovative and entrepreneurial companies in the world.

Syncona Investment Managment Limited

Syncona Investment Management Limited is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to significantly impact the healthcare market of the future.

Vertex Pharmaceuticals (Europe) Ltd

Vertex creates new possibilities in medicine. Our team discovers, develops and commercializes innovative therapies so people with serious diseases can lead better lives.

EY

Ernst & Young is one of the world's leading business and financial advisers, helping clients to operate efficiently, profitably and successfully. Our UK firm is a multi-discipline professional services organisation providing a wide range of assurance and consulting services to the business and public sectors. We are committed to providing value to our clients and achieving our vision of being recognised as the professional services firm that contributes most to its clients' success.

AstraZeneca

AstraZeneca is a major contributor to UK science and innovation investment, economic prosperity and to patient health. The UK is home to the organisations global headquarters and major research and development and manufacturing facilities. AstraZeneca invest over £1.3 billion per year in research and development in the UK.

BioScience Managers

CellCentric Ltd

CellCentric is a drug discovery company focused on epigenetics, a major new area for novel small molecule therapeutics. The company is pursuing novel treatments for prostate, breast and amongst other cancers.

GW Pharmaceuticals Plc

GW Pharmaceuticals was founded in 1998 and listed on AIM, a market of the London Stock Exchange, in June 2001. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines, including Sativex® Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications. GW has assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW maintains in-house control over all aspects of the cannabinoid product development process - botanical research, extraction technology, formulation into drug delivery technologies, clinical trials and regulatory affairs. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.

Bird & Bird

Recognised as the 'World's Leading Law Firm for Life Sciences' by Who's Who Legal for four consecutive years, Bird & Bird's International Life Sciences group have unexcelled experience.

Wellcome Sanger Institute

The mission of the Wellcome Trust Sanger Institute is to use genome sequences to improve human health by advancing understanding of the biology of humans and pathogens.

OxStem

KPMG

Vaccitech

SV Health Managers

Benevolent AI

Stevenage Bioscience Catalyst

Bit Bio

Closed Loop Medicine

Arecor

MedAnnex

Kymab Limited

Our strategy is to use our pioneering technology to grow our in-house drug discovery and development pipeline, as well as partner with others to maximise the technology's application in the development of novel medicines.

JnJ Innovations

Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success.

Norton Rose Fulbright LLP

Norton Rose Fulbright is a full service, global law firm with over 3800 lawyers based in more than 50 cities internationally.

Dechert LLP

Dechert is a leading international law firm with 21 offices in the United States, Europe and Asia. Founded in 1875, the firm has grown to over 800 lawyers allowing us the resources to deliver seamless, high-quality legal services to clients wherever they do business.

Our clients' success determines our own. We ensure this by collaborating closely with them and working diligently and efficiently to help clients achieve their goals. Guided by a team-oriented philosophy, we encourage ongoing communication with clients to ensure that we understand their objectives and can easily accommodate their changing needs. With in-depth industry knowledge and legal experience, we're able to identify the most complicated issues and focus on what matters most to our clients.

At Dechert, we're committed to high-quality work and exceptional client service. We promote both by recruiting and retaining the best lawyers and professionals in the world and by making training and professional development an integral part of the way we do business."